The Claim
In patients with atherosclerotic cardiovascular disease who achieve LDL-C levels below 70 mg/dL using moderate-intensity statins, escalating lipid-lowering therapy is associated with a 30% lower rate of major adverse cardiovascular and cerebrovascular events, including coronary or peripheral revascularization (MACCE2), with an incidence of 24.5 versus 35.4 events per 1,000 person-years compared to those not escalating therapy, suggesting that further LDL-C reduction may reduce the need for invasive procedures.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If people with heart disease already have low 'bad' cholesterol from statins, going even lower might help avoid heart attacks, strokes, or surgeries like stents.
See the scientific wording
In patients with atherosclerotic cardiovascular disease who achieve LDL-C levels below 70 mg/dL using moderate-intensity statins, escalating lipid-lowering therapy is associated with a 30% lower rate of major adverse cardiovascular and cerebrovascular events including coronary or peripheral revascularization (MACCE2), with an incidence of 24.5 versus 35.4 events per 1,000 person-years in non-escalation patients, suggesting that further LDL-C reduction may reduce the need for invasive procedures.
What the research says
1 studyThe study found that stepping up cholesterol treatment after reaching a good level helped avoid more heart procedures, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.